G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia
Jing Fang,Jing Fang,Lyndsey Bolanos,Kwangmin Choi,Xiaona Liu,Susanne Christie,Shailaja Akunuru,Rupali Kumar,Dehua Wang,Xiaoting Chen,Kenneth D. Greis,Peter Stoilov,Marie Dominique Filippi,Jaroslaw P. Maciejewski,Guillermo Garcia-Manero,Matthew T. Weirauch,Nathan Salomonis,Hartmut Geiger,Yi Zheng,Daniel T. Starczynowski,Daniel T. Starczynowski +20 more
TL;DR: The results implicate Ub signaling in coordinating RNA processing by TLR pathways during an immune response and in premalignant hematologic diseases, such as MDS.
Journal ArticleDOI
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.
Karen W.L. Yee,Anne E. Hagey,Srdan Verstovsek,Jorge E. Cortes,Guillermo Garcia-Manero,Susan O'Brien,Stefan Faderl,Deborah A. Thomas,William G. Wierda,Steven M. Kornblau,Alessandra Ferrajoli,Maher Albitar,Evelyn McKeegan,David R. Grimm,Toby Mueller,Rhonda R. Holley-Shanks,Leonardo Sahelijo,Gary Gordon,Hagop M. Kantarjian,Francis J. Giles +19 more
TL;DR: The maximum tolerated dose and toxicities of ABT-751 in patients with advanced myelodysplastic syndrome and relapsed or refractory acute leukemias were determined and a previously undescribed nonsynonymous single nucleotide polymorphism was identified in exon 4 of the β-tubulin gene, TUBB, in three other patients.
Journal ArticleDOI
Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?
Elias Jabbour,Hagop M. Kantarjian,Susan O'Brien,Jianqin Shan,Alfonso Quintás-Cardama,Guillermo Garcia-Manero,Mary Beth Rios,Jorge E. Cortes +7 more
TL;DR: It is proposed that achievement ofCCyR and partial cytogenetic response at 3 months should be considered optimal and suboptimal responses, respectively, and the achievement of MMR offered no advantage over CCyR in defining long-term outcome in patients with newly diagnosed CML treated with second-generation TKIs.
Journal ArticleDOI
A pilot pharmacokinetic study of oral azacitidine
TL;DR: Oral azacitidine is bioavailable in humans and should be studied in formal phase 1 trials, according to the results of a formulation feasibility pilot study.
Journal ArticleDOI
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine‐based regimens
William G. Wierda,Susan O'Brien,Stefan Faderl,Alessandra Ferrajoli,Xuemei Wang,Kim Anh Do,Guillermo Garcia-Manero,Deborah A. Thomas,Jorge E. Cortes,Farhad Ravandi-Kashani,Francis J. Giles,Susan Lerner,Hagop M. Kantarjian,Michael J. Keating +13 more
TL;DR: The objective of the current analysis was to determine whether improvements in treatment have had an impact on survival for patients with CLL.